FOPM 2
THE PATENT ACT 1970
(39 of 1970)
&
The Patents Rules, 2003
COMPLETE SPECIFICATION
(See section 10 and rule 13)
1. TITLE OF THE INVENTION: AMORPHOUS WANXABAN AND PROCESS FOR PREPARATION OF THE SAME.
2 . APPLICANT (S)
(a) NAME: Wanbury Ltd.
(b) NATIONALITY: An Indian Company incorporated under the Indian Companies ACT 1956.
(c) ADDRESS:
Wanbury Ltd., BSEL Tech park, B-wing, 10th floor, sec -30A, opp. Vashi Railway station, Vashi, Navi- Mumbai-400703, India.
3. PREAMBLE TO THE DESCRIPTION
The following specification particularly describes the invention and the manner in which it is to be performed.

AMORPHOUS WANXABAN AND PROCESS FOR PREPARATION OF THE SAME
TECHNICAL FIELD OF THE INVENTION:
The present invention relates to an amorphous form of 5-chloro-.N-formyl-.N- ({ (5S) -2-oxo-3- [4- (3-oxomorpholin-4-y 1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam ide compound of the formula (I) (Also refer as Wanxaban) and the process for preparation of the same.
The present invention further relates to an amorphous co-precipitateof5-chloro-N-formyl-N- ({ (5S) -2-oxo-3- [4- (3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thio phene-2-carboxamide compound of the formula (I) and the process for preparation of the same.

The present invention also relates to an amorphous form of 5-chloro-N-formyl-N- ({ (5S) -2-oxo-3- [4- (3-oxomorpholin-4-y 1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam ide compound of the formula (I) with pharmaceutically acceptable excipients and the process for preparation of the same.
The present invention also relates to an amorphous

co-precipitates of 5-chloro-N-formyl-IV- ({ (5S) -2-oxo-3 -[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}meth yl)thiophene-2-carboxam-ide compound of the formula (I) with pharmaceutically acceptable excipients and the process for preparation of the same.
BACKGROUND OF THE INVENTION:
5-chloro-N-formyl-N- ({ (5S) -2-oxo-3- [4- (3-oxomorpholin-4-y 1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam -ide compound of formula (I) is a Pro-drug of the class of anti-coagulant drugs which is now under the investigation for the anticoagulant activity and is represented by compound of the formula (I) shown below.

The parent drug Rivaroxaban is a micronized drug and it is practically insoluble in water. Therefore the aforementioned compound of the formula (I) is expected to behave same like parent drug. In accordance with that, amorphous form of aforementioned compound of the formula (I) may play a vital role in its activity. In view of this basis, there is a practical and scientific need to develop an amorphous form of the compound of formula (I) and the process for the preparation of the same.

An amorphous form can be thought of as liquid that has been solidified by the removal of thermal energy or a solvent, in a manner that circumvents crystallization. The amorphous form can have different solubility, stability, and mechanical behavior that can be exploited by pharmaceutical scientists. The solubility of a given solid is a sum of crystal packing energy, cavitations, and solvation energy. Different crystalline forms of a given drug will have different crystal packing energies. The amorphous form of the same drug requires minimal packing energy disruption when dissolving due to absence of an ordered crystal lattice. Thus, the amorphous form provides the maximal solubility advantage as compared to the crystalline forms of a drug. The 'apparent solubility' and dissolution advantage offered by these systems is a vital approach to enhance bioavailability of poorly water soluble drugs.
PCT Publication No. 2014/102822 describe use of 5-chloro-N-f ormyl-N- ({ (5S) -2-oxo-3- [4- (3-oxomorpholin-4-y 1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam -ide compound of the formula (I) as a pro-drug in treatment of prophylaxis of diseases, pulmonary embolism. It also describe process for the preparation of 5-chloro-N-formyl -N-({(5S)-2-OXO-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3 -oxazolidin-5-yl} methyl) thiophene-2-carboxamide compound of the formula (I) as shown below in Scheme-I.

OBJECTS OF THE INVENTION:
An objective of the invention is to provide, an amorphous co-precipitates of compound of the formula (I).
Yet another objective of the invention is to provide amorphous co-precipitates of compound of the formula (I) with pharmaceutically acceptable excipients.
Yet another objective of the invention is to provide, preferably the amorphous co-precipitates forms of compound of the formula (I) with pharmaceutically acceptable excipients having X-ray diffraction pattern as shown in Figure-1.
Yet another objective of the invention is to provide, a process for the preparation of essentially amorphous co-precipitates form of compound of the formula (I).
Yet another objective of the invention is to provide, an amorphous form of compound of the formula (I).
Yet another objective of the invention is to provide, amorphous form of compound of the formula (I) having X-ray diffraction pattern as shown in Figure-2.
Yet another objective of the invention is to provide, a process for the preparation of amorphous form of compound of the formula (I).

Yet another objective of the invention is to provide, pharmaceutical compositions; comprising amorphous form of compound of the formula (I) or amorphous co-precipitates of compound of the formula (I) having improved solubility properties and therefore have improved bioavailability.
SUMMARY OF THE INVENTION:
According to first aspect, the present invention relates to an amorphous form of compound of the formula (I).
According to another aspect, the present invention relates to a process for the preparation of an amorphous form of 5-chloro-N-formyl-N-({ (5S) -2-oxo-3-[4-(3-oxomorpholin-4-y 1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam -ide compound of the formula (I) , the said process comprising:
a) providing a solution of 5-chloro-N-f ormyl-N-
({(5S)-2-OXO-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, compound of the formula (I) thereof in a solvent; and
b) removing the said solvent to isolate the solid mass which
is amorphous or essentially amorphous form of 5-chloro-
N-formyl-N- ({ (5S) -2-oxo-3- [4- (3-oxomorpholin-4-yl) ph
-enyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carbox
-amide compound of the formula(I).
According to another aspect, the present invention relates to pharmaceutical composition comprising amorphous form of

compound of the formula (I) with pharmaceutically acceptable excipients.
Second aspect of the present invention is to provide, an amorphous co-precipitates of compound of the formula (I).
According to another aspect, the present invention relates to amorphous co-precipitates of compound of the formula (I) with pharmaceutically acceptable excipients.
According to another aspect, the present invention relates to a process for the preparation of essentially amorphous co-precipitates form of compound of the formula (I).
According to another aspect, the present invention relates to a process for the preparation of an amorphous co-precipitates of 5-chloro-N-formyl-N- ({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)t hiophene-2-carboxamide, compound of the formula (I) with pharmaceutically acceptable excipients, the said process comprising:
a) providing a solution of 5-chloro-N-formyl-N-
({(5S)-2-OXO-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-o xazolidin-5-yl}methyl)thiophene-2-carboxamide compound of the formula (I) thereof in a solvent;
b) mixing the above solution with the solution of
pharmaceutically acceptable excipients; and

c) removing the said solvent to isolate the solid mass which is amorphous or essentially amorphous co-precipitates of5-chloro-IV-formyl-N- ({ (5S) -2-oxo-3- [4- (3-oxomorpho -lin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophe ne-2-carboxamide compound of the formula (I) with pharmaceutically acceptable excipients.
BREIF DESCRIPTION OF THE DRAWING:
Figure-1: powder X-ray diffraction (PXRD) pattern of an amorphous co-precipitate of formula (I) with pharmaceutically acceptable excipients prepared according to Example 1 & 2.
Figure-2: powder X-ray diffraction (PXRD) pattern of an amorphous form of compound of the formula (I) prepared according to Example 3 & 4.
DETAIL DESCRIPTION OF THE INVENTION:
Unless define otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any method and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described.
Unless stated to the contrary, any use of the words such as "including" "containing," "comprising," "having" and the

like, means "including without limitation" and shall not be construed to limit any general statement that it follows to the specific or similar items or matters immediately following it. Embodiments of the invention are not mutually exclusive, but may be implemented in various combinations. The describe embodiments of the invention and the disclose examples are given for the purpose of illustration rather than limitation of the invention as set forth the appended claims.
For the purpose of the present invention, the following terms are defined below:
The term "co-precipitate" means that the compositions comprise amorphous compound of the formula (I) together with at least one pharmaceutically acceptable carrier, being prepared by removing solvent from solution containing both of them.
The term "pharmaceutically acceptable" means, which is useful in preparing a pharmaceutical composition that is generally non-toxic and is not biologically undesirable and includes that which is acceptable for human pharmaceutical use.
The term "composition includes, but is not limited to, a powder, a suspension, an emulsion and/or mixture thereof. The term composition is intended to encompass a product containing the specified ingredients in the specified amounts, as well as any product, which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. A "composition" may content a single compound or a

mixture of compounds. A "compound" is a chemical substance that includes molecules of the same chemical structure regardless of its three dimensional orientation. Thus, it may be used to indicate racemates, stereoisomers, or both.
The term "pharmaceutical composition"is intended to encompass a product including the active ingredient(s) , pharmaceutically acceptable excipients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical composition of the present invention encompass, any composition made by admixing the active ingredient, additional active ingredient(s), and pharmaceutically acceptable excipients.
The term excipients mean a component of a pharmaceutical product that is not the active ingredient, such as filler, diluent, carrier, and so on. The excipents that are useful in preparing a pharmaceutical composition are preferably generally safe, nontoxic and neither biologically nor otherwise undesirable, and are acceptable for veterinary use as well as human pharmaceutical use. "A pharmaceutically acceptable excipent" as used in the specification and claims includes both one and more than one such excipient.
The pharmaceutically acceptable excipients that may be used for the preparation of co-precipitates includes; but not

limited to, pharmaceutically hydrophilic or hydrophobic excipients for instance in case of hydrophilic excipients such as povidones, gums, cellulose derivatives, cyclodextrins, gelatins, hypromellose phthalate, sugars, polyhydric alcohols etc. The use of more than one of the pharmaceutical excipient to provide the desired release profile or the enhancement of stability is within the scope of the invention.
The co-precipitates of the present invention may have improved physiochemical characteristics that will achieve the effective delivery of compound of the formula (I).
The co-precipitates of the present inventions increase the stability of amorphous form of compound of the formula (I) and they enhance the integrity of the amorphous nature in-totality throughout their life cycle.
The co-precipitates of compound of the formula (I) with pharmaceutically acceptable excipients namely; povidone, is characterized by powder X-ray diffraction (PXRD) pattern as shown in Figure-1.
In one aspect of the present invention, there is provided amorphous co-precipitates of compound of the formula (I).
An amorphous material do not exhibit the three-dimensional long-range order found in crystalline materials but is structurally more similar to liquids where the arrangement of molecules is random. Amorphous solids are not crystalline and therefore do not give a definitive X-ray diffraction (XRD)

pattern, in addition they do not give rise to a melting point and tend to liquefy at some point beyond the glass transition point. The X-ray diffractogram was measured on Bruker Axe, DS advance Power X-ray Diffractometer with CuK alpha-I Radiation source having the wavelength 1.541 A0.
In one embodiment, the present invention provides an amorphous co-precipitates of 5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3 -oxazolidin-5-yl} methyl) thiophene-2- carboxamide compound of the formula (I) .
In another embodiment, the present invention provides a process for the preparation of an amorphous co-precipitates of 5-chloro-N-formyl-N- ({ (5S)-2-oxo-3-[4-(3-oxomorpholin -4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carb oxamide compound of the formula (I) with pharmaceutically acceptable excipients, the said process comprising:
a) providing a solution of 5-chloro-N-formyl-N-
({ (5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1, 3-o xazolidin-5-yl}methyl)thiophene-2-carboxamide compound of the formula (I) thereof in a solvent;
b) mixing the above solution with the solution of pharmaceutically acceptable excipients; and
c) removing the said solvent to isolate the solid mass which is amorphous or essentially amorphous co-precipitates of5-chloro-N-formyl-N- ({ (5S)-2-oxo-3-[4-(3-oxomorpho 1in-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophen

e-2-carboxamide compound of the formula (I) with pharmaceutically acceptable excipients.
In another embodiment, the present invention provides an amorphous form of 5-chloro-N-formyl-N-({(5S) -2-oxo -3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}me thyl)thiophene-2-carboxam-ide compound of the formula (I).
In another embodiment, the present invention provides a process for the preparation of an amorphous form of 5-chloro-N-formyl-N- ({ (5S) -2-oxo-3- [4- (3-oxomorpholin-4-y 1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam ide compound of the formula (I) , the said process comprising:
a) providing a solution of 5-chloro-N-formyl-N-
({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-o xazolidin-5-yl}methyl)thiophene-2-carboxamide compound of the formula (I) thereof in a solvent; and
b) removing the said solvent to isolate the solid mass which
is amorphous or essentially amorphous form of 5-chloro-
N-formyl-N- ({ (5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)ph
-enyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carbox
amide compound of the formula (I).
5-chloro-N-formyl-N- ({ (5S) -2-oxo-3- [4- (3-oxomorpholin-4-y 1)phenyl]-1, 3-oxazolidin-5-yl}methyl)thiophene-2-carboxam ide compound of the formula (I) used herein can be either in amorphous or crystalline form, or a mixture of crystalline and amorphous form, solvate form or hydrates form thereof.

The solution of 5-chloro-IV-formyl-N- ({ (55) -2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methy 1) thiophene-2-carboxamide compound of the formula (I) thereof in a solvent, may be obtained by dissolving compound of the formula (I) in a suitable solvent, or such a solution may be obtained directly from reaction mass or from work-up procedure, in which compound of the formula (I) is formed.
The mixing of obtained solution of compound of the formula (I) and the solution of pharmaceutically acceptable excipients may be done by various ways but not limited to: preparing two different solutions separately followed by their mixing, or prepare single solution by adding both components, solution may be prepare at higher temperature depending on the solubility of the components, or it may be obtain directly from the reaction mass or during its work-up procedures etc.
The solvent used herein may includes but not limited to alcohols, hydrocarbons, ketones, ethers, halogenated hydrocarbons, nitriles, esters, dimethylsulfoxide, dimethylformamdie, dimethylacetamide, dioxane, or pyrolidones or mixtures thereof. Preferably the said solvent is dichloromethane, ethyl acetate, and acetonitrile or mixtures thereof.
The dissolution temperature to prepare the solution of compound of the formula (I) with pharmaceutically acceptable excipients can range between 10°C and 120°C. (or reflux

temperature of the solvent/mixture). Any other temperature is also acceptable as long as a clear solution is obtained. The quantity of the solvent used for the dissolution depends on the solvent and adopted dissolution temperature. The obtained solution can be optionally treated with carbon for removal of undesired color or with sodium sulfate for moisture removal. The obtained solution may be treated for removal of any undesired particles by subjecting to filtration, centrifugation, decantation and other techniques.
The removal of the solvent may be affected at an increased temperature, preferably at reflux temperature and/or at reduced pressure. The removal of solvent is carried out by filtration, distillation, evaporation, atmospheric distillation, distillation under reduced pressure, lypholization, freeze drying, spray drying, agitated thin film drying etc.
The solid residue obtained after solvent removal may be isolated and dried using conventional methods. The advantage of the process includes simplicity, eco-friendliness and suitability for commercial use.
Distillation of the solvent may be carried out under high vacuum and elevated temperatures depending upon the solvents used for the preparing the solution. Any other temperature and vacuum conditions can be used as long as there is no increase in the impurity level of the product due to decomposition. The drying may be done at atmospheric pressure or reduced pressure for suitable period. The temperature,

pressure and period can be chosen based on the volatility of the solvent used for the preparation of solution. The dried material can be optionally milled to get desired particle size.
In another embodiment of the invention there does provided pharmaceutical composition comprise an amorphous co-precipitates of compound of the formula (I) with pharmaceutically acceptable excipients.
In another embodiment of the invention there is provided pharmaceutical composition comprising an amorphous form of compound of the formula (I) and pharmaceutically acceptable excipients.
EXAMPLES:
The present invention is described with reference of the following examples. However these examples are for illustrative purpose only and not to be construed as limitations on the scope of the invention.
Example 1: Preparation of amorphous co-precipitates of 5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-y 1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam ide compound of the formula (I).
5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-y 1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam ide (5.0 grams) was dissolved in dichloromethane (100 ml)

stirred and for 15 minutes to obtain clear solution at a temperature 25°C to 30°C. To this solution added solution of Polyvinyl pyrrolidone (PVP) (5.0 grams) in dichloromethane (100 ml) at a temperature 25°C to 30°C. The resulting mixture was stirred for 1 hour. The dichloromethane was removed under reduced pressure to obtain amorphous co-precipitates of 5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-y 1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam ide compound of the formula (I).
Example 2: Preparation of essentially amorphous co-precipitatesof5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3 -oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thi ophene-2-carboxamide compound of the formula (I).
5-chloro-N-formyl-N- ({ (5S) -2-oxo-3.- [4- (3-oxomorpholin-4-y 1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam ide (5.0 grams) was dissolved in acetonitrile (65 ml) at a reflux temperature to obtain clear solution. To this hot clear solution added a solution of Polyvinyl pyrrolidone (PVP) (5.0 grams) in acetonitrile (50 ml) at a temperature 75°C to 80°C. The resulting mixture was cooled to 25°C to 30°C. To this solution added ethyl acetate (60 ml) . Distill off the solvents under reduced pressure to obtain the amorphous co-precipitates of 5-chloro-N-formyl-N-({ (5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methy 1)thiophene-2-carboxamide compound of the formula (I).
Example 3: Preparation of amorphous form of 5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-y

1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam ide compound of the formula (I).
5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-y 1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam ide (5.0 grams) was dissolved in dichloromethane (125 ml) and stirred forl5 minutes to obtain clear solution at a temperature 25°C to 30°C. The dichloromethane was removed under reduced pressure to obtain amorphous form of 5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-y 1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam ide compound of the formula (I).
Example-4:Preparation of amorphous form of 5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-y 1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam ide compound of the formula (I).
5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-y 1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam ide (5.0 grams) was dissolved in acetonitrile (50 ml) at 80°C and stirred forl5 minutes to obtain clear solution at a temperature 75°C to '80°C. The acetonitrile was removed under reduced pressure to obtain amorphous form of 5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-y 1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam ide compound of the formula (I).
Example 5: Preparation of amorphous co-precipitates of 5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-y

1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam ide compound of the formula (I).
5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-y 1)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxam ide (5.0 grams) was dissolved in acetonitrile (50 ml) at a reflux temperature to obtain clear solution. To this hot clear solution added Polyvinyl pyrrolidone (PVP) (5.0 g) at a temperature 75°C to 80°C. The resulting mixture was cooled to 25°C to 30°C to obtain solid. The resulting solid was filtered to obtain amorphous co-precipitates of 5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carbo xamide compound of the formula (I).

WE CLAIM:
1. An amorphous form of 5-chloro-N-formyl-N- ({ (55) -2-oxo
-3-[4-(3-oxomorpholin -4-yl)phenyl]-1,3-oxazolidin
-5-yl}methyl)thiophene-2-carboxamide compound of the
formula (I) having powder X-ray diffraction pattern as
shown in Figure-2.

2. A process for the preparation of an amorphous form of
5-chloro-N-formyl-N- ({ (5S) -2-oxo-3- [4- (3-oxomorpholin-
4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-
carboxamide compound of the formula (I) , the said process
comprising:
a) providing a solution of 5-chloro-N-formyl-N- ({(55) -2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazol idin-5-yl)methyl)thiophene-2-carboxamide compound of the formula (I) in a solvent; and
b) removing the solvent from solution obtained in step a) to isolate the solid mass which is amorphous or essentially amorphous form of 5-chloro- N-formyl-N- ({ (55) -2-OXO-3-[4-(3-oxomorpholin-4-yl)phenyl]-1, 3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide compound of the formula (I).

3. A process for the preparation of an amorphous co-precipitates of 5-chloro-N-formyl-N-({ (5S) -2-oxo -3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl} methyl)thiophene-2-carboxamide compound of the formula (I) with pharmaceutically acceptable excipients, the said process comprising:
a) providing a solution of 5-chloro-Af-formyl-N- ({(5S) -2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazol idin-5-yl)methyl)thiophene-2-carboxamide compound of the formula (I) thereof in a solvent;
b) mixing the above solution with the solution of pharmaceutically acceptable excipients; and
c) removing the solvent to isolate the solid mass which is amorphous or essentially amorphous co-precipitates of5-chloro-N-formyl-N- ({ (5S) -2-oxo-3-[4-(3-oxomorph olin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thioph ene-2-carboxamide compound of the formula (I) with pharmaceutically acceptable excipients.
4 . The process according to claim 2 and 3, wherein the solution of5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholi n-4-yl)phenyl]-1,3-oxazolidin-5-y1}methyl)thiophene-2-carboxamide compound of the formula (I) thereof in a solvent, was obtained by dissolving compound of the formula (I) in a suitable solvent, or such a solution was obtained directly from reaction mass or from work-up procedure, in

which compound of the formula (I) is formed.
5. The process according to claim 3, wherein the mixing of solution of compound of the formula (I) and the solution of pharmaceutically acceptable excipients was done by various ways but not limited to preparing two different solutions separately followed by their mixing, or prepare single solution by adding both components, solution was prepare at higher temperature depending on the solubility of the components, or it was obtain directly from the reaction mass or during its work-up procedures etc.
6. The process according to claim 2, 3 and 4, wherein the solvent used are selected from the group consisting of alcohols, hydrocarbons, ketones, ethers, halogenated hydrocarbons, nitriles, esters, dimethylsulfoxide, dimethylformamdie, dimethylacetamide, dioxane, or pyrolidones or mixtures thereof. Preferably the said solvent is dichloromethane, ethyl acetate, and acetonitrile or mixtures thereof.
7. An amorphous co-precipitates form of 5-chloro-N-formyl-N-
({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxa zolidin-5-yl}methyl)thiophene-2-carboxamide compound of the formula (I) having powder X-ray diffraction pattern as shown in Figure-1.
8. The process according to claim 2 and 3, wherein the removal
of the solvent was affected at an increased temperature,
preferably at reflux temperature and/or at reduced

pressure. The removal of solvent was carried out by filtration, distillation, evaporation, atmospheric distillation, distillation under reduced pressure, lypholization, freeze drying, spray drying, agitated thin film drying etc.
9. A pharmaceutical composition comprising amorphous
co-precipitates of compound of the formula (I) with
pharmaceutically acceptable excipients.
10. A pharmaceutical composition comprising an amorphous
form of compound of the formula (I) and pharmaceutically
acceptable excipients.